ImmuPharma PLC (IMM) — Tangible Net Worth Ratio
ImmuPharma PLC (IMM) has a Tangible Net Worth Ratio of 98.5% as of June 2025. This metric is calculated by deducting intangible assets (GBX5.00K) from net assets (GBX336.70K) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See ImmuPharma PLC short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
ImmuPharma PLC Tangible Net Worth Ratio (2004–2023)
This chart shows how ImmuPharma PLC's Tangible Net Worth Ratio has changed across 21 annual periods from 2004 to 2023. As of June 2025, the ratio stands at 98.5%, reflecting net assets of GBX336.70K with intangible assets of GBX5.00K GBX. See operational self-sufficiency of ImmuPharma PLC to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for ImmuPharma PLC (2004–2023)
The table below presents the year-by-year Tangible Net Worth Ratio for ImmuPharma PLC from 2004 to 2023, covering 21 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see ImmuPharma PLC market capitalisation.
| Year | Tangible NW Ratio | Net Assets (GBX) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 57.6% | GBX1.06 Million | GBX447.57K | GBX2.72 Million | ▼ -23.6 pp |
| 2022 | 81.2% | GBX2.52 Million | GBX473.89K | GBX3.97 Million | ▼ -8.0 pp |
| 2021 | 89.2% | GBX4.41 Million | GBX477.55K | GBX6.00 Million | ▼ -5.8 pp |
| 2020 | 95.0% | GBX9.65 Million | GBX484.04K | GBX10.92 Million | ▲ +4.1 pp |
| 2019 | 90.9% | GBX5.27 Million | GBX478.96K | GBX5.80 Million | ▼ -2.8 pp |
| 2018 | 93.7% | GBX7.62 Million | GBX483.04K | GBX8.66 Million | ▲ +7.2 pp |
| 2017 | 86.5% | GBX3.57 Million | GBX482.27K | GBX5.02 Million | ▼ -4.3 pp |
| 2016 | 90.8% | GBX5.55 Million | GBX511.09K | GBX6.71 Million | ▲ +21.7 pp |
| 2015 | 69.1% | GBX1.69 Million | GBX522.46K | GBX3.21 Million | ▼ -21.1 pp |
| 2014 | 90.2% | GBX5.71 Million | GBX560.54K | GBX7.07 Million | ▲ +1.3 pp |
| 2013 | 88.9% | GBX5.40 Million | GBX602.07K | GBX7.21 Million | ▼ -3.7 pp |
| 2012 | 92.5% | GBX8.42 Million | GBX627.68K | GBX10.51 Million | ▼ -2.1 pp |
| 2011 | 94.7% | GBX12.51 Million | GBX666.00K | GBX14.28 Million | ▼ -0.9 pp |
| 2010 | 95.6% | GBX15.97 Million | GBX705.00K | GBX17.55 Million | ▼ -0.3 pp |
| 2009 | 95.9% | GBX18.08 Million | GBX747.00K | GBX24.64 Million | ▲ +3.1 pp |
| 2008 | 92.8% | GBX11.24 Million | GBX809.00K | GBX13.40 Million | ▲ +17.6 pp |
| 2007 | 75.2% | GBX3.05 Million | GBX755.00K | GBX4.10 Million | ▼ -12.0 pp |
| 2006 | 87.3% | GBX5.89 Million | GBX749.00K | GBX7.33 Million | ▲ +17.8 pp |
| 2006 | 69.4% | GBX2.50 Million | GBX765.00K | GBX3.63 Million | ▼ -30.6 pp |
| 2005 | 100.0% | GBX993.00K | GBX0.00 | GBX1.01 Million | ▲ +0.0 pp |
| 2004 | 100.0% | GBX978.00K | GBX0.00 | GBX980.00K | — |